Kenneth Cundy

Prior to joining Anebulo, Dr. Cundy served as Chief Scientific Officer at CohBar, Inc., a publicly-traded biotechnology company developing therapeutics targeting chronic and age-related diseases, where he built a technology platform around peptides encoded in the mitochondrial genome, advancing the lead program to successful clinical proof of concept for NASH and obesity. Before CohBar, Dr. Cundy was Chief Scientific Officer at XenoPort, Inc., a biopharmaceutical company focused on therapeutics for neurological disorders. He was coinventor of XenoPort’s approved drug Horizant®, leading efforts from discovery to development including approval for the treatment of postherpetic neuralgia and restless legs syndrome in the US and Japan. Previously, Dr. Cundy held various positions at Gilead Sciences, Inc. where he was coinventor of the blockbuster drug tenofovir DF (Viread®) and a key contributor to the larger antiviral franchise, including Hepsera®, Vistide®, and Tamifu®.

Dr. Cundy started his scientific career at Sterling Winthrop, a pharmaceutical division of Eastman Kodak Company, where he developed novel formulation technologies exploiting Kodak’s historical capabilities. He was coinventor of Nanocrystal® technology used in many approved drug products.

Dr. Cundy received a B.S. in pharmacy from the University of Manchester and registered as a pharmacist in the United Kingdom before earning a Ph.D. in pharmaceutical sciences from the University of Kentucky and postdoctoral training in Biochemistry at the University of California, Berkeley.